Indole-3-Carbinol
4 benefits mapped to clinical evidence across supplements.
Dose per serving from products
65 products in our catalogue print how much Indole-3-Carbinol a serving holds.
Most common: 100 mg to 250 mg, 54% of 65 products.
| Dose per serving | Products |
|---|---|
| 10 mg or less | 3 |
| 10 mg to 25 mg | 3 |
| 25 mg to 50 mg | 5 |
| 50 mg to 100 mg | 10 |
| 100 mg to 250 mg | 35 |
| 250 mg to 500 mg | 9 |
Dose per serving from research
7 study groups in 5 studies say how much Indole-3-Carbinol participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mg to 500 mg, 71% of 7 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mg to 250 mg | 2 |
| 250 mg to 500 mg | 5 |
Benefit Evidence
Estrogen ratio up, +4.55
Tamoxifen metabolites down, endoxifen
CIN regression, 50%
Estrogen ratio up, +4.55
Tamoxifen metabolites down, endoxifen
CIN regression, 50%
Research sources
Hormone balance (5)
- A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen
PubMed ID: 28560655
DIM RCT produced a large increase in urinary 2-OHE1:16α-OHE1 ratio and raised SHBG—direct, high-quality evidence for estrogen-metabolism modulation.
- Long-term responses of women to indole-3-carbinol or a high fiber diet
PubMed ID: 7827590
Randomized oral I3C increased protective 2-hydroxy estrogen metabolites vs placebo—direct, sustained hormone-metabolism effect.
- Harnessing the Power of Cruciferous Vegetables: Developing a Biomarker for Brassica Vegetable Consumption Using Urinary 3,3'-Diindolylmethane
PubMed ID: 27538743
Dose–response human feeding trial validated urinary DIM as an uptake biomarker—supports that dietary I3C/DIM reach systemic levels to affect hormones.
- Placebo-controlled trial of indole-3-carbinol in the treatment of CIN
PubMed ID: 10926790
Oral I3C increased 2/16 ratio dose-dependently in a clinical trial, linking to clinical lesion outcomes.
- A randomized, double-blind, placebo-controlled, cross-over trial to evaluate the effect of EstroSense(®) on 2-hydroxyestrone:16α-hydroxyestrone ratio in premenopausal women
PubMed ID: 36201753
Large multi-ingredient trial (includes I3C) markedly increased urinary 2-OHE1:16α-OHE1 ratio, though confounded by other ingredients.
Women's health (4)
- A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen
PubMed ID: 28560655
DIM RCT raised favorable estrogen-metabolite ratio and SHBG in women (including those on tamoxifen), relevant to breast-cancer-related biomarkers (but reduced tamoxifen metabolites).
- Long-term responses of women to indole-3-carbinol or a high fiber diet
PubMed ID: 7827590
I3C RCT increased protective 2-hydroxy estrogen metabolites linked epidemiologically to lower breast cancer risk.
- Placebo-controlled trial of indole-3-carbinol in the treatment of CIN
PubMed ID: 10926790
I3C increased protective estrogen metabolites in a clinical cervical trial; effect on breast endpoints is indirect but relevant.
- A randomized, double-blind, placebo-controlled, cross-over trial to evaluate the effect of EstroSense(®) on 2-hydroxyestrone:16α-hydroxyestrone ratio in premenopausal women
PubMed ID: 36201753
Multi-ingredient nutraceutical containing I3C produced a marked increase in urinary 2-OHE1:16α-OHE1 ratio; product confounded by other actives.
Cell health (3)
- Placebo-controlled trial of indole-3-carbinol in the treatment of CIN
PubMed ID: 10926790
Oral I3C increased regression of cervical intraepithelial neoplasia and shifted estrogen metabolism toward protective metabolites—direct clinical cellular benefit.
- A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen
PubMed ID: 28560655
DIM trial raised protective estrogen metabolite ratio and SHBG in tamoxifen-treated women—biomarkers linked to cellular protection (but with drug-interaction caveat).
- Long-term responses of women to indole-3-carbinol or a high fiber diet
PubMed ID: 7827590
Sustained favorable estrogen-metabolite changes after I3C are linked to cellular health endpoints.
Detoxification (3)
- Long-term responses of women to indole-3-carbinol or a high fiber diet
PubMed ID: 7827590
I3C shifted estrogen metabolism toward 2-hydroxy metabolites, reflecting altered detoxification/metabolic processing of estrogens.
- Placebo-controlled trial of indole-3-carbinol in the treatment of CIN
PubMed ID: 10926790
Clinical I3C use altered estrogen metabolite ratios (detox-style metabolic shift) alongside lesion regression.
- A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen
PubMed ID: 28560655
DIM changed estrogen metabolism and increased SHBG but also significantly lowered active tamoxifen metabolites—clear interaction with drug metabolism/detox pathways.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Indole-3-Carbinol
Search all101 products whose verified label declares Indole-3-Carbinol — not every bottle that mentions it in a title.